Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 10,8 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. artemisweg 105 8239 dd lelystad - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 10,8 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

orifarm a/s energivej 15 5260 odense (denemarken) - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 10,8 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer, - goserelin

Belanda - Belanda - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bmodesto b.v. artemisweg 105 8239 dd lelystad - goserelineacetaat samenstelling overeenkomend met ; ; gosereline 10,8 mg/stuk - implantatietablet - melkzuur(d,l)-glycolzuur copolymeer - goserelin

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 10.8 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)] . in controlled studies of patients with advanced prostatic cancer comparing zoladex 3.6 mg to orchiectomy, the long-term endocrine responses and objective responses were similar between the two treatment arms. additionally, duration of survival was similar between the two treatment arms in a major comparative trial. in controlled studies of patients with advanced prostatic cancer, zoladex 10.8 mg implant produced pharmacodynamically similar effect in terms of suppression of serum testosterone to that achieved wit

Lithuania - Lithuania - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - goserelinas - implantas užpildytame švirkšte - 10,8 mg - goserelin

Belgium - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

astrazeneca sa-nv - goserelineacetaat - eq. gosereline 3,6 mg - implantaat - 3,6 mg - goserelineacetaat - goserelin

Belgium - Belanda - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

astrazeneca sa-nv - goserelineacetaat - eq. gosereline 10,8 mg - implantaat - 10,8 mg - goserelineacetaat - goserelin

Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

endomedica gmbh (8801636) - goserelinacetat (1:x) ((mit angaben zum essigsäure-gehalt)) - fertigspritze mit implantat - 3,6 mg - teil 1 - fertigspritze mit implantat; goserelinacetat (1:x) ((mit angaben zum essigsäure-gehalt)) (24071) 4,1 milligramm

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - goserelin acetate 12.5mg equivalent to 10.8 mg goserelin - subcutaneous implant - 10.8 mg - active: goserelin acetate 12.5mg equivalent to 10.8 mg goserelin excipient: poly(lactide) polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.